Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

Phase 3 Terminated 237 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to learn if long-term treatment with DVS SR is safe for treating the pain and other symptoms associated with diabetic peripheral neuropathy.

Timeline

Start: 2006-07
Primary completion: 2009-01
Completion: 2009-01

Publications

Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. J Pain Res. 2014 Jun 23;7:339-51. doi: 10.2147/JPR.S55682. eCollection 2014.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desvenlafaxine	Other / unclassified	100 mg	—
Subject	Desvenlafaxine	Other / unclassified	200 mg	—
Subject	Desvenlafaxine	Other / unclassified	400 mg	—

Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

Summary

Timeline

Publications

Drugs

Indications